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Neglected Tropical Diseases (NTDs) represent a plethora of 
infections (17 according to WHO)1 caused by various pathogenic 
agents, such as viruses, bacteria, protozoa and helminths, which 
affect population in developing countries in Africa, Asia and 
America.  Human African Trypanosomiasis (HAT) and 
American trypanosomiasis or Chagas disease are among the 
diseases which received the minimum interest and funding from 
the pharmaceutical industry and therefore called as the most 
neglected diseases.2 Trypanosomatids, flaggelated Kinetoplastida 
protozoan, are the cause of trypanosomiasis and display two main 
strains that infect humans: Trypanosoma brucei and 
Trypanosoma cruzi, which correspond to the two types of 
trypanosomiasis. 
Tuberculosis (TB) is one of the three major microbial lethal 
threats, alongside HIV/AIDS and malaria, to humans history in 
developing and industrialized countries worldwide. WHO 
estimates that there were 1.6 million TB deaths in 2017, and 0.3 
million deaths resulting from coinfection of TB and HIV.3 
Mycobacterium tuberculosis (Mtb), the etiologic pathogen agent 
of TB, is being investigated to find new targets for antitubercular 
therapy. Besides the gravity of the disease, TB receives 
insufficient funding and research for new drugs is less intense 
compared to other diseases. Only two new drugs have been 
approved, bedaquiline and delamanid, to complement the current 
four-drug regimen over the last 60 years.4  
 
 
 
 
 
 
 
 
Figure 1. Derivatives with trypanocidal and tuberculocidal activity. 
 
Various reports in literature display functionalized piperazine 
backbones of derivatives with trypanocidal activity.5,6 Based on 
our previous work on adamantane substituted derivatives with 
pharmacological activity against trypanosomiasis,7-12 we now 
describe the preparation of a series of adamantane diphenoxy 
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alkylamines Ia-f and IIa-f (Figure 2). The new adducts possess 
the adamantane core connected through a phenoxy moiety to the 
side chain of alkylamine. The termini of their side chains consist 
of a piperazine moiety, with a variety of substituents (derivatives 
Ia-c). In addition, morpholine and diethanolamine were used as 
more polar functional groups at the same site.  
In derivatives Id-f and IIa-f the ethanolamine side chain was 
modified to 1-amino-2-propanol, which is an important feature in 
diverse antimicrobial agents.13-16 Moreover, this β-aminoalcohol 
motif has been linked with antimycobacterial action.  
 Ethambutol17 is the main representative of this category of 
antitubercular agents. The 1,2-diamine congeners, such as the 
adamantane derivative SQ-10918,19 and the camphane 
aminoalcohols20 exhibit very low toxicity and improved 
pharmacokinetic properties. Our lab has also reported 
antimycobacterial adamantane derivatives21-23 bearing a 
diarylmethane scaffold.24 
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Figure 2. Diphenoxyadamantane alkylamines Ia-f and IIa-f. 
The synthesis of the new adamantane piperazines Ia-c is depicted 
in Scheme 1. 
The starting material, 2,2-adamantanediyl-di(4-phenol) 125 is 
acylated to form the diester 2. This ethoxycarbonylmethylation is 
accomplished in the presence of sodium hydride in DMF, under 
heating at 80 oC for 72 h, generating first the phenoxy anion, 
which subsequently reacts with ethyl chloroacetate in the 
presence of cat. sodium iodide. Sodium iodide promotes halogen 
exchange and accelerates the nucleophilic substitution. Lower 
temperature or shorter heating time afforded a mixture of 
monoacylated and diacylated esters in a ratio of 1:2. Moreover, 
the use of sodium carbonate in acetone leads to the 
monosubstituted adduct. Reduction of the diester 2 with lithium 
aluminum hydride in dry THF gave dialcohol 3, which was 
functionalized with methane sulfonyl chloride in the presence of 
pyridine to afford the corresponding methane sulfonate 4. The 
latter was treated with the appropriate piperazine to give the 
desired adamantane piperazines Ia-c. 
For comparison purposes, adamantane phenylpiperazine Ib was 
also synthesized by the reaction sequence shown in Scheme 2. 
 In the second synthetic pathway, diphenoxyethyl acetate 2 was 
converted to the diphenylacetimide 6 via the intermediate 
chloride 5. The diester 2 was saponified to the corresponding 
acid, treated with thionyl chloride and then converted to 
diacylchloride 5. The latter was coupled with 1-phenylpiperazine 
to afford the diphenylacetamide 6, which was reduced by lithium 
aluminum hydride in dry THF to the respective phenylpiperazine 
Ib. The second synthetic route gives Ib in an overall yield of 
19% (from the ester), whilst the first method in 24%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Reagents and conditions: (a) NaH / DMF dry; (b) NaI, ethyl chloroacetate, 80 oC, 72 h; (c) i. LiAlH4 / THF, rt, 2 h, ii. H2O/OH-, ~ 0 oC; (d) 
MsCl/Py/THF-EtOH or n-BuOH, 40 oC, 1 h; (e) appropriate piperazine, Δ, 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: (a) NaOH / EtOH-H2O, reflux; (b) SOCl2, reflux; (c) benzene; (d) appropriate piperazine, Δ, 1 h; (e) i. LiAlH4 / THF, Δ, 1 h, 
ii. H2O/OH-, ~ 0 oC
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The preparation of 2-hydroxypropylene derivatives Id-f and IIa-f 
is shown in Scheme 3. 
The method for the epoxide formation of the two isomeric 
alcohols, 4,4’-(adamantane-2,2-diyl)diphenol (1) and 4,4’-
(adamantane-1,3-diyl)diphenol  (7)26, has been patented,27 and 
followed only for the generation of the phenoxy anion. 
Thereafter, as a result of considerable experimentation, we 
modified the procedure as follows: portions of sodium hydroxide 
were added over a period of 2 h into a mixture of the 
corresponding diphenol and epichlorohydrin in MIBK and 
DMSO, which was heated at 45 oC. Subsequently, the 
temperature of the reaction mixture was increased to 75 oC and 
after 4 h, the desired disubstituted epoxide 8 was produced. 
However, the 1,3-substituded isomeric phenol 7 did not give a 
sole product, but a mixture of mono and double substituted 
epoxide in a ratio of 1:5. To rectify this, the 4,4’-(adamantane-
1,3-diyl)diphenol  (7) was heated, instead, for 24 h to give the 
1,3-bis(4-glycidyloxyphenyl)adamantane (9) in 81.5% yield. 
The O-alkylation of phenols with epichlorohydrin is well 
documented in literature28,29. Apart from the formation of 3-
aryloxy-1,2-epoxypropane i, the epoxide ring opening affords the 
chloroalcohol ii30 (Figure 3). The IR spectral data confirmed the 
formation of the respective open-form chloroalcohol; IR v (OH) 
= 3556 cm-1 in the case of diphenol 1 and IR v (OH) = 3436 cm-1 
in the case of diphenol 7. 
The coupling of the corresponding amine with either of the O-
alkylated diphenols 1 and 7 leads to the same final 
aminoalcohols. Aminalcohols Id-f and IIa-f were prepared by 
two different methods, either under conventional heating in an 
autoclave or microwave irradiation using i-PrOH as solvent in 
both of methods. 
The in vitro results from the anti-T.brucei screening are 
summarized in Table 1. 
The 1-methylpiperazine derivatives Ia, Id and IIc seem to be 
more potent in comparison to their congeners. Bulky substituents, 
such as 1-phenylpiperazine and 1-(4-fluoromethyl)-
phenylpiperazine, have a negative impact on potency. Moreover, 
the ethanolamine spacer seems to enhance the trypanocidal 
activity, while the 2-hydroxypropylene linker in the side chain 
decreases the positive role in potency of the end groups. 
Derivatives Id and IIc have lower activity than the Ia adduct. On 
the other hand, the amimoalkane groups at the functional end of 
the side chains (derivatives IId, IIe and IIf) corroborate the 
argument that small substituents enhance the activity. The 4 
carbon atom length of the amino substitution seems to enhance 
the activity.The butylamine derivative IIe was found more active 
than its congeners. Based on the promising trypanocidal potency 
of 1-methylpiperazine derivative Ia (SI=6.5, the ratio of IC50 
values obtained with L6 cells and T. brucei), we will prompt our 
efforts toward decreasing the cytotoxicity of future analogues. 
The in vitro antimycobacterial test results of the new adamantane 
derivatives against replicating M. tuberculosis H37Rv and non-
replicating SS18b, assessed by REMA,31-33 are presented in 
Table 2. 
The antimycobacterial activity of the 1-methylpiperazine adducts 
Ia and Id is notable, whilst IIc’s is marginal. On the other hand, 
aminoalkanes IIe and IIf seem to have the best activity against 
M. tuberculosis. The bulky substitution is proven, and in this 
case, to a have negative impact on the antimycobacterial efficacy. 
The polar heads at the side chain (congener If) do not enhance 
the antimycobacterial activity, either. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: a) epichlorohydrin, NaOH / MIBK-DMSO dry, 45 oC, 2 h; (b) 75 oC, 24 h; (c) appropriate amine, i-PrOH, 110 oC, 
autoclave, 24 h; (d) appropriate amine, i-PrOH, 110 oC, microwave, 30 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Mechanism of O-alkylation of phenol. 
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Table 1  
Trypanocidal activity of the most active diphenoxyadamantane 
alkylamines Ia-f and IIa-f
Table 2  
Antimycobacterial  activity of most active diphenoxyadamantane 
alkylamines Ia-f and IIa-f
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aIC50 and IC90; concentration that inhibits growth by 50% and 90%, 
respectively 
 
 
 
 
 
 
 
 
 
aMIC: minimum inhibition concentration 
 
  
The new adamantane derivatives presented herein are doubly 
substituted by a phenoxyl, incorporating various aminoalkyl side 
chains. The 1-methylpiperazine derivative Ia is the most active 
against T. brucei, while hexylamine IIf exhibits the higher 
antimycobacterial potency among its analogs. The ethylene 
spacer of the side chain leads to enhanced activity compared to 
the 2-hydroxypropylene linker. These preliminary results will be 
utilized in future studies on phenyl-substituted adamantane 
derivatives with a trypanocidal and antitubercular potency devoid 
of toxicity against mammalian cells. 
Appendix A. Supplementary data  
Supplementary data to this article can be found online at  
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